Search results for "Severity of illne"

showing 10 items of 1114 documents

LAight® Therapy Significantly Enhances Treatment Efficacy of 16 Weeks of Topical Clindamycin Solution in Hurley I and II Hidradenitis Suppurativa: Re…

2021

<b><i>Background:</i></b> Hidradenitis suppurativa (HS) is a chronic, inflammatory, burdensome skin disease where medical first-line treatment is still limited to long-term, topical and/or systemic antibiotics. The RELIEVE study aimed at evaluating the efficacy of LAight® therapy – a combination of intense pulsed light and radiofrequency – as an adjunct treatment to first-line therapies in Hurley stage I and II HS. <b><i>Methods:</i></b> The RELIEVE study was performed as a two-period multicenter randomized controlled trial with blinded assessment. For period A from week 0 to week 16, the 88 participating subjects were randomized into either a…

medicine.medical_specialtymedicine.medical_treatmentDermatologyIntense pulsed lightSeverity of Illness Indexlaw.inventionRandomized controlled trialQuality of lifelawInternal medicineClinical endpointMedicineHumansHidradenitis suppurativabusiness.industryClindamycinClindamycinmedicine.diseaseTreatment efficacyAnti-Bacterial AgentsHidradenitis SuppurativaTreatment OutcomeTopical clindamycinChronic DiseaseQuality of Lifebusinessmedicine.drugDermatology (Basel, Switzerland)
researchProduct

Are biological drugs effective and safe in older severe asthmatics?

2019

Introduction: The treatment of asthma in older ages follows the recommendations of international guidelines for the management of asthma in younger ages, although older age has always represented an exclusion criterion for eligibility to pharmacological trials. This poses a clinical challenge when deciding whether elderly severe asthmatics are candidates for biological drugs. Areas covered: The current article has a narrative structure to review the current literature on efficacy and safety of novel pharmacological drugs against immunoglobulins and interleukins that mediate and orchestrate the main inflammatory pathways in severe asthma, in order to explore whether older subjects (i.e. >…

medicine.medical_specialtypulmonary eosinophilia/drug therapyeducationImmunoglobulinsmonoclonal030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-asthmatic AgentSeverity of Illness IndexBiological drugs03 medical and health sciences0302 clinical medicineimmune system diseasesInternal medicineSeverity of illnessImmunoglobulinHumansMedicineAnti-Asthmatic AgentPharmacology (medical)Age FactorAnti-Asthmatic AgentsAsthmaAgedRandomized Controlled Trials as TopicBiological ProductsAsthma/drug therapybiologyhumanizedbusiness.industryInterleukinsAge FactorsGeneral MedicineInterleukinmedicine.diseaseAsthmarespiratory tract diseasesantibodie030220 oncology & carcinogenesisMonoclonalPractice Guidelines as Topicbiology.proteinBiological Productanti-asthmatic agents/pharmacologyAntibodybusinessHuman
researchProduct

Sex Differences in Severity of Stroke in the INSTRUCT Study: a Meta‐Analysis of Individual Participant Data

2018

Background Women have worse outcomes after stroke than men, and this may be partly explained by stroke severity. We examined factors contributing to sex differences in severity of acute stroke assessed by the National Institutes of Health Stroke Scale. Methods and Results We pooled individual participant data with National Institutes of Health Stroke Scale assessment (N=6343) from 8 population‐based stroke incidence studies (1996–2014), forming part of INSTRUCT (International Stroke Outcomes Study). Information on sociodemographics, stroke‐related clinical factors, comorbidities, and pre‐stroke function were obtained. Within each study, relative risk regression using log‐binominal modeling…

medicine.medical_specialtysex differencePopulation030204 cardiovascular system & hematologyGlobal HealthRisk AssessmentSeverity of Illness IndexBrain IschemiaBrain ischemia03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineEpidemiologySeverity of illnessmedicineHumanscardiovascular diseasesSex DistributioneducationStrokeIntracerebral hemorrhageeducation.field_of_studyQuality and OutcomesSystematic Review and Meta‐analysisbusiness.industryIncidenceMeta Analysismedicine.diseasestrokeMeta-analysisRelative riskepidemiologyCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryJournal of the American Heart Association
researchProduct

Is COVID‐19 infection more severe in kidney transplant recipients?

2021

International audience; There are no studies which have compared the risk of severe Covid-19 and related mortality between transplant recipients and non-transplant patients. We enrolled two groups of patients hospitalized for Covid-19, i.e., kidney transplant recipients from the French Registry of Solid Organ Transplant (n=306) and a single-center cohort of non-transplant patients (n=795). An analysis was performed among subgroups matched for age and risk factors for severe Covid-19 or mortality. Severe Covid-19 was defined as admission (or transfer) to an intensive care unit, need for mechanical ventilation, or death.Transplant recipients were younger and had more comorbidities compared to…

medicine.medical_treatment[SDV]Life Sciences [q-bio]MESH: Registries*AucunMESH: Comorbidity030230 surgerylaw.inventionchemistry.chemical_compound0302 clinical medicinelawcardiovascular diseaseMESH: Risk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesclinical research / practiceImmunology and AllergyCumulative incidencePharmacology (medical)kidney transplantation / nephrologyMESH: IncidenceMESH: AgedUnivariate analysisMESH: France / epidemiologyMESH: Middle AgedMESH: Transplant Recipients / statistics & numerical data*Acute kidney injuryIntensive care unit3. Good healthMESH: COVID-19 / epidemiologyCohort[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesglomerular filtration rate (GFR)kidney failure / injurymedicine.medical_specialtyinfection and infectious agents - viralinfectious diseaseBrief CommunicationMESH: Graft Rejection / prevention & control03 medical and health sciencesInternal medicineDiabetes mellitusMESH: Severity of Illness IndexMESH: COVID-19 / diagnosis*medicineHumansMESH: SARS-CoV-2Mechanical ventilationCreatinineTransplantationMESH: Humansbusiness.industrySARS-CoV-2MESH: Graft Rejection / epidemiology*COVID-19MESH: Retrospective Studiesmedicine.diseaseKidney TransplantationTransplant RecipientsMESH: Maleimmunosuppressive regimensMESH: Immunosuppressive Agents / therapeutic useMESH: Pandemics*MESH: Propensity Score*chemistryReinfectionMESH: Immunosuppression / methodsMESH: Intensive Care UnitsbusinessMESH: FemaleMESH: Kidney Transplantation*
researchProduct

European guidelines on chronic mesenteric ischaemia - joint United European Gastroenterology, European Association for Gastroenterology, Endoscopy an…

2020

Chronic mesenteric ischaemia is a severe and incapacitating disease, causing complaints of post-prandial pain, fear of eating and weight loss. Even though chronic mesenteric ischaemia may progress to acute mesenteric ischaemia, chronic mesenteric ischaemia remains an underappreciated and undertreated disease entity. Probable explanations are the lack of knowledge and awareness among physicians and the lack of a gold standard diagnostic test. The underappreciation of this disease results in diagnostic delays, underdiagnosis and undertreating of patients with chronic mesenteric ischaemia, potentially resulting in fatal acute mesenteric ischaemia. This guideline provides a comprehensive overvi…

mesenteric artery stentingComputed Tomography AngiographyFOCUSED UPDATEContrast MediaARTERY COMPRESSION SYNDROMEDiseaseGuidelineSettore MED/22 - Chirurgia VascolareSeverity of Illness Indexatherosclerosi0302 clinical medicineIschemiaMesenteric Vascular Occlusionatherosclerosis; coeliac artery release; Median arcuate ligament syndrome; mesenteric arteries; mesenteric artery stenting610 Medicine & healthMesenteric arteriesmesenteric arteriesSocieties MedicalNetherlandsSUPERIOREvidence-Based MedicineGASTRIC EXERCISE TONOMETRYmedicine.diagnostic_testGastroenterologyDUAL ANTIPLATELET THERAPYENHANCED MR-ANGIOGRAPHYEuropeTreatment Outcomemedicine.anatomical_structureOncology030220 oncology & carcinogenesisRadiological weaponSURGICAL-TREATMENT030211 gastroenterology & hepatologyRadiologyMedian arcuate ligament syndromeSTENT PLACEMENTmedicine.medical_specialtyANTITHROMBOTIC THERAPYMedian arcuate ligament syndromeRisk Assessment03 medical and health sciencescoeliac artery releasemedicineHumanscardiovascular diseasesIntensive care medicinePatient Care TeamMEDIAN ARCUATE LIGAMENTbusiness.industryGold standardEndoscopyGuidelinemesenteric arteriemedicine.diseaseEndoscopyMesenteric ischemiaMesenteric IschemiaChronic DiseaseInterdisciplinary CommunicationatherosclerosisbusinessMagnetic Resonance Angiography
researchProduct

Treatment of Knee Osteoarthritis with Bone Marrow-Derived Mononuclear Cell Injection: 12-Month Follow-up.

2018

Objectives To evaluate the main symptoms of knee osteoarthritis (OA) and tissue structure changes after a single dose bone marrow–derived mononuclear cell (BM MNC) intra articular injection. Case series study. Patients with knee OA Kellgren Lawrence (K-L) grade II and III received 1 injection of BM MNC. The clinical results were analyzed with the Knee injury and Osteoarthritis Outcome Score (KOOS) and Knee Society Score (KSS) before, 3, 6, and 12 months after injection. Radiological evaluation was performed with a calibrated x-ray and the magnetic resonance (MR) imaging before and 6 to 7 months postinjection. Results A total of 34 knees were treated with BM MNC injections. Mean (±SD) age of…

musculoskeletal diseasesAdultMalePathologymedicine.medical_specialtyKnee JointBiomedical EngineeringPhysical Therapy Sports Therapy and RehabilitationArticular cartilageOsteoarthritisPeripheral blood mononuclear cellSeverity of Illness IndexInjections Intra-Articular03 medical and health sciences0302 clinical medicineIntra articularClinical PapersmedicineImmunology and AllergyHumans030203 arthritis & rheumatologybusiness.industryHematopoietic Stem Cell Transplantation030229 sport sciencesMiddle AgedOsteoarthritis Kneemedicine.diseaseMagnetic Resonance ImagingRadiographymedicine.anatomical_structureTreatment OutcomeLeukocytes MononuclearFemaleBone marrowStem cellbusinessMonth follow upFollow-Up StudiesCartilage
researchProduct

Pain and clinical findings in the low back: a study of industrial employees with 5-, 10-, and 28-year follow-ups.

2009

Little is known about the relationships of clinical findings in the low back with low back pain (LBP) in the normal working population. We studied whether physiotherapist's findings in the low back were associated with local and radiating LBP among a cohort (n=902) of employees in the engineering industry. A systematic non-proportional sample was drawn in strata by age, gender, and occupational class. The non-proportionality aimed at increasing sample size in smaller strata. Physiotherapists performed the straight-leg raising test (SRL), and made assessments of the fingertip-to-floor distance and pain in palpation of the lumbar interspinous spaces. The variables on pain at the interspinous …

musculoskeletal diseasesAdultMalemedicine.medical_specialtyLogistic regressionSeverity of Illness IndexPhysical medicine and rehabilitationhealth services administrationSeverity of illnessmedicineCluster AnalysisHumansGeneralizability theoryProspective StudiesProspective cohort studyWorkplaceReferred painbusiness.industryMiddle AgedLow back painHealth Surveysbody regionsAnesthesiology and Pain MedicineLogistic ModelsSample size determinationCohortPhysical therapypopulation characteristicsFemalemedicine.symptombusinessLow Back PainFollow-Up StudiesEuropean journal of pain (London, England)
researchProduct

A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analy…

2018

Abstract Background Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis. Aims We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis. Methods 118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up. Results Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in…

musculoskeletal diseasesModerate to severeAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaBiologicDisease durationAdalimumab; Biologics; Golimumab; Ulcerative colitis; Adalimumab; Adult; Antibodies Monoclonal; Colitis Ulcerative; Female; Humans; Italy; Logistic Models; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alphaUlcerativeBiologicsGolimumabSeverity of Illness IndexTreatment failureAntibodies03 medical and health sciences0302 clinical medicineInternal medicineMonoclonalAdalimumabmedicineHumansskin and connective tissue diseasesAdalimumab; Biologics; Golimumab; Ulcerative colitis; Hepatology; GastroenterologyPropensity ScoreProportional Hazards ModelsHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyAdalimumabAntibodies MonoclonalMiddle Agedmedicine.diseaseColitisUlcerative colitishumanitiesGolimumabLogistic ModelsTreatment OutcomeUlcerative colitisItaly030220 oncology & carcinogenesisPropensity score matching030211 gastroenterology & hepatologyColitis UlcerativeFemalebusinessmedicine.drug
researchProduct

Decreasing muscle performance associated with increasing disease activity in patients with rheumatoid arthritis

2018

Objectives Increasing evidence suggests that inflammation has a detrimental effect on muscle strength. Our objective was to analyse the association between muscle performance and different disease activity levels in patients with rheumatoid arthritis (RA). Method A total of 199 consecutive outpatients were subject to cross-sectional assessment. Measurements of grip strength, endurance of the upper and lower limbs and trunk strength were combined as a muscle performance composite score (MPCS), using a standardised method. The disease activity for 28 joints (DAS28), radiographs of small joints (Larsen score), rheumatoid factor, body mass index (BMI), comorbidities and anti-rheumatic drugs wer…

nivelreumarheumatoid arthritisMaleINACTIVITYArthritislcsh:MedicineMuscle ProteinsComorbidityBiochemistrySeverity of Illness IndexArthritis RheumatoidGrip strength0302 clinical medicineRisk FactorsSTRENGTHCACHEXIAMedicine and Health SciencesCRITERIAPublic and Occupational Health030212 general & internal medicinelcsh:ScienceMusculoskeletal SystemINDEXPain Measurement2. Zero hungerMultidisciplinaryMusclesWOMENta3141Muscle AnalysisMiddle AgedSports Science3. Good healthBioassays and Physiological AnalysisRheumatoid arthritisStrength TrainingFemaleBONE-MINERAL DENSITYAnatomylihaskuntoResearch Articlemedicine.medical_specialtymuscle fitnessStrength trainingHEALTHY CONTROLSImmunologyRheumatoid ArthritisResearch and Analysis MethodsAutoimmune Diseases03 medical and health sciencesRheumatologyInternal medicineHand strengthmedicineRheumatoid factorHumansMuscle StrengthRisk factorSports and Exercise MedicineMuscle SkeletalExercise030203 arthritis & rheumatologybusiness.industryArthritislcsh:RENERGY-EXPENDITUREBeck Depression InventoryBiology and Life SciencesProteinsPhysical Activitymedicine.diseaseJoints (Anatomy)PHYSICAL-ACTIVITYCross-Sectional StudiesSkeletal MusclesPhysical Fitness3121 General medicine internal medicine and other clinical medicinemuscle strengthPhysical Endurancelcsh:QClinical ImmunologyClinical MedicinebusinesslihasvoimaPLoS ONE
researchProduct

COVID Obesity: A One-Year Narrative Review

2021

On 11 March 2020, coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization (WHO). This study focuses on a narrative review about the illness during the first year of the pandemic in relation to obesity. Databases were used to search studies published up to 8 December 2020. In total, 4430 articles and other scientific literature were found, and 24 articles were included in this one-year narrative review. The mean BMI value of severe COVID-19 patients ranged from 24.5 to 33.4 kg/m2, versus 2 for non-severe patients. Articles using the terms obesity or overweight without indicating the BMI value in these patients were common, but this is not useful, as the a…

obesityReviewComorbidityScientific literature030204 cardiovascular system & hematologyOverweightSeverity of Illness IndexCOVID obesityBody Mass IndexBMI03 medical and health sciences0302 clinical medicinePandemicSeverity of illnessHumansoverweightMedicineTX341-641030212 general & internal medicineEpidemiologiaPandemicsNutrition and DieteticsSARS-CoV-2Nutrition. Foods and food supplybusiness.industryCOVID-19Anthropometrymedicine.diseaseObesityComorbiditynutritionTrastorns de la nutricióObesitatmedicine.symptombusinessBody mass indexFood ScienceDemographyNutrients
researchProduct